Multiple Myeloma Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Multiple Myeloma stocks.

Multiple Myeloma Stocks Recent News

Date Stock Title
Mar 28 BMY Bristol Myers Squibb: The Comeback Is Unfolding
Mar 28 BMY Bristol Myers drug Zeposia fails Phase 3 study for Crohn's disease
Mar 28 BMY UPDATE 2-Bristol Myers' bowel disease drug fails in late-stage study
Mar 28 BMY Bristol Myers Squibb Announces Pivotal KRYSTAL-12 Confirmatory Trial Evaluating KRAZATI (adagrasib) Meets Primary Endpoint of Progression-Free Survival for Patients with Pretreated KRASG12C-Mutated Locally Advanced or Metastatic Non-Small Cell Lung…
Mar 28 BMY Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s Disease
Mar 28 BMY Is Bristol Myers Squibb Stock a Buy?
Mar 28 ACLX Insiders Are Dumping These 10 Healthcare Stocks
Mar 28 BMY Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results
Mar 28 CCCC Here’s Why Meridian Small Cap Growth Fund Trimmed C4 Therapeutics (CCCC)
Mar 27 ADAP Results of Adaptimmune's SPEARHEAD-1 Trial with Afami-cel in Advanced Sarcomas Published in the Lancet
Mar 27 BMY Bristol Myers Squibb (BMY) Rises Higher Than Market: Key Facts
Mar 27 ACLX Insider Sell: Arcellx Inc's Chief Medical Officer Christopher Heery Disposes of 46,815 Shares
Mar 26 BMY 20 Countries with the Highest Heart Disease Deaths Per Capita
Mar 26 BMY Bristol Myers Squibb Expands Health Equity Grant Initiatives to Improve Health Outcomes
Mar 25 GMAB Transactions in Connection with Share Buy-back Program
Mar 25 BMY Bristol-Myers Squibb Company (BMY) Impacted by Delay in New Product Launches
Mar 25 BMY Bristol Myers Squibb to Present Data at the American College of Cardiology Annual Scientific Session 2024 Reinforcing Extensive Body of Evidence in Clinical and Real-World Settings Across Cardiovascular Portfolio
Mar 22 BMY Bristol-Myers Squibb (NYSE:BMY) Has Announced A Dividend Of $0.60
Multiple Myeloma

Multiple myeloma, also known as plasma cell myeloma, is a cancer of plasma cells, a type of white blood cell normally responsible for producing antibodies. Often, no symptoms are noticed initially. When advanced, bone pain, bleeding, frequent infections, and anemia may occur. Complications may include amyloidosis.The cause is unknown. Risk factors include obesity, radiation exposure, family history, and certain chemicals. The underlying mechanism involves abnormal plasma cells producing abnormal antibodies which can cause kidney problems and overly thick blood. The plasma cells can also form a mass in the bone marrow or soft tissue. When only one mass is present, it is known as a plasmacytoma, while more than one is known as multiple myeloma. Multiple myeloma is diagnosed based on blood or urine tests finding abnormal antibodies, bone marrow biopsy finding cancerous plasma cells, and medical imaging finding bone lesions. Another common finding is high blood calcium levels.Multiple myeloma is considered treatable, but generally incurable. Remissions may be brought about with steroids, chemotherapy, targeted therapy, and stem cell transplant. Bisphosphonates and radiation therapy are sometimes used to reduce pain from bone lesions.Globally, multiple myeloma affected 488,000 people and resulted in 101,100 deaths in 2015. In the United States, it develops in 6.5 per 100,000 people per year and 0.7% of people are affected at some point in their lives. It usually occurs around the age of 61 and is more common in men than women. It is uncommon before the age of 40. Without treatment, typical survival is seven months. With current treatments, survival is usually 4–5 years. This gives a five-year survival rate around 49%. The word myeloma is from the Greek myelo- meaning "marrow" and -oma meaning "tumor".

Browse All Tags